A change of name sometimes go beyond just a twitch in identity as the move [to re-brand] could serve as a catalyst for massive growth. This is definitely the intention of the management of ScriptDash, the digital pharmacy startup which was recently renamed ‘Alto’, a Latin word which means ‘elevate’ and in the words of Mattieu Gamache-Asselin [who is one of the co-founders of the company], the re-branding is aimed at raising the standard of service delivery in the pharmacy sector. To this effect, a sum of $23 million has been set aside to finance the project which would eventually see the company spreading its tentacles beyond its current domain.
A glimpse at the company’s operations
There are quite a few other pharmaceutical startups- aside Alto- that operate within certain cities: for instance ZappRX in Boston; Capsule in New York and Zipdrug but Alto has indeed taken a quantum leap above others- this is not to discountenance the impact and effectiveness of these other ones- as they (Alto) look to push beyond the San Francisco Bay Area [where the startup has thus far attended to 12,000 clients dispensing over 100,000 prescriptions since its inception]. The company is now canvassing for a nationwide outreach.
The prerogative of the startup is to bridge the communication gap between doctors and pharmacies: this is addressed through the creation of a technological support system that would enhance the delivery of prescriptions. Furthermore, the company intends to modernize the process thereby bringing it up to speed with the ever dynamic world of digital technology and also easing up the flow of service from on-board service providers to bback-end users- the clients.
However, one notable challenge that has been experienced with the system is the tendency of new clients to bypass the setup. To address this concern, the company will need to liaise with doctors who will come in [as some sort of middlemen] between the (new) clients and the system. Such measure should definitely make the venture more profitable since it would ensure that most of the prescriptions are ordered (for) and delivered through the back-end system. Overall, this would serve as a basis for maintaining the company’s viability since it will not limited to delivering prescriptions solely through refills which according to Alto’s co-founder, Vlad Blumen, only account for a meagre fraction of pharmacy business.
The rebranding is no doubt a huge step- and one in the right direction- but with this kind of expansion being envisaged having never been embarked on before now in the orb of digital pharmacy, it remains to be seen how this paradigm shift leads to the imprinting of the name, Alto in the sands of time.